Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Essa Pharma (NASDAQ: EPIX) shares cratered 73% from $5.20 to $1.40 Friday after the company said it was terminating its Phase II trial (NCT05075577) assessing masofaniten combined with enzalutamide vs
Ozempic and Wegovy are in a class of medications known as GLP-1 receptor agonists
They also havent shared if people who apply and are denied can reapply before the programs end date in December 2027
Missed Dose: If a patient misses a scheduled injection, they should contact their healthcare provider for advice
US$ 24.20
US$ 21.90
US$ 23.28
